Results 111 to 120 of about 28,189 (202)

The roles of CymA in support of the respiratory flexibility of Shewanella oneidensisMR-1 [PDF]

, 2012
Akagawamatsushita, Atkinson, Beliaev, Beliaev, Bordi, Burns, Cruz-Garcia, David J. Richardson, Dos Santos, Duncan G.G. McMillan, Firer-Sherwood, Gao, Gates, Gescher, Gralnick, Itoh, James K. Fredrickson, John M. Zachara, Julea N. Butt, Lars J.C. Jeuken, Liang Shi, Lies, Maier, Marritt, McMillan, Myers, Myers, Myers, Myers, Pinchuk, Pinchuk, Pitts, Ross, Schuetz, Schutz, Schwalb, Shi, Shirodkar, Simon, Sophie J. Marritt, Sundararajan, Venkateswaran   +41 more
core   +1 more source

Esclerosis múltiple: estudio observacional de práctica clínica habitual con fármacos orales de prímera línea: teriflunomida y dimetilfumarato [PDF]

, 2017
Teriflunomida y dimetil fumarato son dos fármacos orales recientemente aprobados como terapias modificadoras de la enfermedad (TME) de primera línea para la esclerosis múltiple, con una eficacia muy similar a las TME parenterales convencionales y la ...
Miguel Toquero, Raquel
core  

Real-World Treatment Outcomes in Black, Hispanic, Asian, and White People with Multiple Sclerosis Treated with Fumarates in the USA

Neurology and Therapy
Introduction Multiple sclerosis (MS) is a heterogeneous disease affecting a diverse population. Compared with white people with MS (PwMS), Black PwMS have more severe disease and higher incidence of MS, whereas Hispanic PwMS experience earlier onset ...
Sophia Woodson, Edward J. Gettings, Chu-Yueh Guo, Sylvia Klineova, Jong-Mi Lee, Rebecca S. Romero, Aljoeson Walker, Kinyee Fong, Jason P. Mendoza, Nicholas Belviso, Boyang Bian, James B. Lewin, Sai L. Shankar   +12 more
doaj   +1 more source

Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis

Drug Design, Development and Therapy, 2014
Luigi di Nuzzo,1 Rosamaria Orlando,2 Carla Nasca,1 Ferdinando Nicoletti1,31Department of Physiology and Pharmacology, Sapienza University of Rome, 2IRCCS Associazione Oasi Maria S.S., Institute for Research on Mental Retardation and Brain Aging, Troina ...
di Nuzzo L, Orlando R, Nasca C, Nicoletti F   +3 more
doaj  

Metabolomics analysis of children with autism, idiopathic-developmental delays, and Down syndrome. [PDF]

, 2019
Although developmental delays affect learning, language, and behavior, some evidence suggests the presence of disturbances in metabolism are associated with psychiatric disorders.
Abbeduto, Leonard, Hertz-Picciotto, Irva, Orozco, Jennie Sotelo, Slupsky, Carolyn M   +3 more
core   +1 more source

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations

Therapeutics and Clinical Risk Management, 2016
Luca Prosperini, Simona Pontecorvo Department of Neurology and Psychiatry, Sapienza University, Rome, Italy Abstract: Delayed-release dimethyl fumarate (DMF), also known as gastroresistant DMF, is the most recently approved oral disease-modifying ...
Prosperini L, Pontecorvo S
doaj  

Oncometabolite fumarate facilitates PD-L1 expression and immune evasion in clear cell renal cell carcinoma

Cell Death and Disease
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), with a rising incidence worldwide. However, the mechanisms by which ccRCC evades immune surveillance remain incompletely understood.
Yi Gao, Shiyin Fan, Xue Sun, Jiaxi Li, Yue Dai, Hongchen Li, Haijie Ma, Yanping Xu, Lei Lv   +8 more
doaj   +1 more source

Headache in radiologically isolated syndrome: a hint toward imminent conversion: a case report

Journal of Medical Case Reports
Background Headaches are more prevalent in patients with multiple sclerosis compared with the general population. However, headaches are still considered a rare symptom of multiple sclerosis, especially when they appear as an initial symptom.
Masoud Etemadifar, Hasan Kaveyee, Parto Zohrabi, Amir Mohammad Jozaie, Mehri Salari, Yasin ebne-ali-heydari   +5 more
doaj   +1 more source

Dimethyl fumarate for treating Papillon–Lefèvre syndrome

JAAD Case Reports, 2023
Abdullah Al-Omair, MD, Muteb Alharbi, MD, Asem Almesfer, MD   +2 more
doaj   +1 more source

Is it time to target no evident disease activity (NEDA) in multiple sclerosis? [PDF]

, 2015
Banwell, Bermel, Cohen, Cohen, Coles, Coles, Comi, Confavreux, Dobson, Erbayat Altay, Giovannoni, Giovannoni, Giovannoni, Hartung, Havrdova, Kappos, Leray, Levesque, Miller, Rio, Scalfari, Solomon, Sormani, Sormani, Tuohy, Zivadinov   +25 more
core   +1 more source